Spots Global Cancer Trial Database for Lenalidomide Based Immunotherapy in the Treatment of DLBCL
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Lenalidomide Based Immunotherapy in the Treatment of DLBCL
Official Title: Lenalidomide Based Immunotherapy Efficacy Related Molecular Biomarker in Diffuse Large B-cell Lymphoma
Study ID: NCT03715296
Conditions
Interventions
Study Description
Brief Summary: This study is to evaluate the efficacy related molecular biomarker of Lenalidomide plus RCHOP or RICE in the treatment of de novo or Refractory and Relapsed DLBCL patients
Detailed Description:
Keywords
Eligibility
Minimum Age: 16 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ruijin hospital, Shanghai, Shanghai, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
